# Comparison of continuous positive airway pressure (CPAP) with SOMNOventCR® in patients with combined obstructive sleep apnoea and Cheyne-Stokes respiration

Submission date	Recruitment status  No longer recruiting	<ul><li>Prospectively registered</li></ul>			
08/01/2009		☐ Protocol			
Registration date	ce Overall study status Completed	Statistical analysis plan			
05/02/2009		[X] Results			
<b>Last Edited</b> 18/02/2019	Condition category Nervous System Diseases	Individual participant data			

## Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Dr Wolfgang Galetke

#### Contact details

Institut für Pneumologie an der Universität Witten/Herdecke Aufderhöher Str. 169-175 Solingen Germany 42699

# Additional identifiers

ClinicalTrials.gov (NCT)

NCT00811668

Protocol serial number

Wi\_VentCR\_12/2008

# Study information

#### Scientific Title

Comparison of treatment with continuous positive airway pressure (CPAP) and treatment with adaptive assisted ventilation (SOMNOventCR®) in patients with combined obstructive sleep apnoea and Cheyne-Stokes respiration

#### **Study objectives**

The goal of the study was to compare this new therapeutic option (SOMNOvent CR®) with the established method of continuous positive airway pressure (CPAP) in patients with combination of obstructive sleep-apnoea syndrome and Cheyne-Stokes respiration with underlying heart disease.

## Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Ethics Committee of the University of Witten/Herdecke (Universität Witten/Herdecke e.V.), approved in May 2008 (ref: 13/2008)

#### Study design

Randomised controlled cross-over single-blind single-centre trial

#### Primary study design

Interventional

#### Study type(s)

**Treatment** 

## Health condition(s) or problem(s) studied

Obstructive sleep apnoea, Cheyne-Stokes respiration

#### **Interventions**

This is a cross-over study. CPAP therapy with SOMNOsoft plus® for 4 weeks versus adaptive servo-ventilation therapy with SOMNOvent CR® for 4 weeks. There is a washout period of 1 week between the treatments.

#### **Intervention Type**

Other

#### Phase

Phase IV

#### Primary outcome(s)

The central AHI, assessed by polysomnography at baseline, after four weeks therapy, and (after the wash-out period) after four weeks with the other therapy (i.e. 9 weeks).

## Key secondary outcome(s))

- 1. Total AHI, assessed by polysomnography at baseline, after four weeks therapy, and (after the wash-out period) after four weeks with the other therapy (i.e. 9 weeks)
- 2. Left ventricular ejection fraction, assessed by echocardiography at baseline, after 4 weeks therapy, and (after the wash-out period) after four weeks with the other therapy (i.e. 9 weeks)

- 3. Six minutes walking test at baseline, after 4 weeks therapy, and (after the wash-out period) after four weeks with the other therapy (i.e. 9 weeks)
- 4. Patients' questionnaire at baseline, after 4 weeks therapy, and (after the wash-out period), after four weeks with the other therapy (i.e. 9 weeks). This will include assessment of subjective satisfaction with the therapy.
- 5. Minimum and middle oxygen saturation, assessed by polysomnography at baseline, after four weeks therapy, and (after the wash-out period) after four weeks with the other therapy (i.e. 9 weeks)
- 6. Compliance, after 4 weeks therapy, and (after the wash-out period) after 4 weeks with the other therapy (i.e. 9 weeks)

#### Completion date

31/07/2009

# **Eligibility**

### Key inclusion criteria

- 1. Men and women greater than 18 years
- 2. Diagnosis of arterial hypertension, coronary heart disease or dilative cardiomyopathy
- 3. Combined sleep apnoea syndrome with a total value of apnoea-hypopnoea index (AHI) greater than 15 per hour and a rate up to 20% of central events or periodic breathing

#### Participant type(s)

Patient

## Healthy volunteers allowed

No

#### Age group

Adult

#### Lower age limit

18 years

#### Sex

All

#### Key exclusion criteria

- 1. Heart failure New York Heart Association (NYHA) class IV
- 2. Myocardial infarction, unstable angina pectoris or cardiac surgery within the last three months
- 3. AHI less than 15 per hour
- 4. Obstructive breathing disturbances up to 80%
- 5. Pregnancy
- 6. Absence of declaration of consent
- 7. Malign diseases
- 8. Serious (severe) chronic oxygen-requiring pulmonary illness
- 9. Aged under 18 years

#### Date of first enrolment

13/05/2008

#### Date of final enrolment

31/07/2009

# Locations

#### Countries of recruitment

Germany

Study participating centre
Institut für Pneumologie an der Universität Witten/Herdecke
Solingen
Germany
42699

# Sponsor information

#### Organisation

Bethanien Science Institute (Wissenschaftliches Institut Bethanien e.V.) (Germany)

#### **ROR**

https://ror.org/03ndabk35

# Funder(s)

#### Funder type

University/education

#### **Funder Name**

University of Witten/Herdecke (Universität Witten/Herdecke) (Germany) - Institute for Pneumology (Institut für Pneumologie) (ref: Wi\_VentCR\_12/2008)

# **Results and Publications**

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

# **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/08/2014	18/02/2019	Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes